KNOW Bio, LLC develops nitric oxide-based therapies and precision light treatments to enhance respiratory function and combat resistant bacterial infections. Their proprietary technologies aim to improve patient outcomes in severe respiratory diseases and other medical conditions by redefining treatment standards.
Funding
Funding not disclosed
Founders
Product
Problem
Continuous glucose monitoring (CGM) sensors and insulin infusion sets, critical for diabetes management, trigger a foreign body response (FBR) when inserted under the skin. This FBR limits the long-term accuracy, performance, and patient convenience of these devices. Current devices have short and mismatched lifetimes (7-14 days for CGM sensors and 3 days for insulin infusion sets) due to the FBR.
Solution
Diabetic Health, Inc. develops coatings designed to mitigate the foreign body response (FBR) to continuous glucose monitoring sensors (CGM) and insulin infusion sets, thereby improving their performance and longevity. The company's core technology involves nanoparticles that store and release nitric oxide, an endogenous anti-inflammatory metabolite. These nanoparticles are dispersed in medical-grade polymers and applied as thin films to device surfaces. Once inserted, the coated devices release minute amounts of nitric oxide locally, protecting the device from the FBR and prolonging its functional lifetime.
Target Audience
The primary target audience includes diabetes patients who rely on continuous glucose monitoring (CGM) devices and insulin pumps to manage their blood glucose levels, as well as manufacturers of these devices.
Features
- Nanoparticles that store and release nitric oxide, an anti-inflammatory metabolite.
- Coatings applied as thin films to CGM sensors and insulin infusion sets.
- Localized nitric oxide release to protect devices from the foreign body response.
- Potential to extend the functional lifetime of CGMs and insulin infusion sets.